metronomic cyclophosphamide

Metronomic CPA refers to the use of cyclophosphamide administered in a continuous or frequent low-dose schedule (as opposed to traditional maximum tolerated dose regimens) for cancer therapy. This approach aims to minimize toxicity while maintaining antitumor efficacy. The mechanism of action includes direct cytotoxic effects on tumor cells, inhibition of tumor angiogenesis (by targeting endothelial cells), and modulation of the immune system—potentially reducing regulatory T cell populations and enhancing antitumor immunity. Metronomic CPA is primarily used in palliative settings for metastatic solid tumors such as prostate cancer, breast cancer, ovarian cancer, colorectal cancer, sarcoma, and melanoma. It is often chosen for patients who are heavily pretreated or unfit for intensive chemotherapy due to its favorable toxicity profile[1][2][4][5][8].

Other names

metronomic CPAmetronomic cyclophosphamidelow-dose continuous cyclophosphamide